Literature DB >> 33517895

Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT).

N Guffon1, M Pettazzoni2, N Pangaud3, C Garin4, G Lina-Granade5, C Plault6, C Mottolese7, R Froissart2, A Fouilhoux6.   

Abstract

BACKGROUND: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-term outcomes are known to be improved by HSCT, the long-term cognitive, adaptive and psychosocial functional outcomes of children with (MPSI-H) post-HSCT are not well documented. This manuscript focuses on retrospective long-term follow-up (7-33 years) of 25 MPSI-H patients, transplanted between 1986 and 2011.
RESULTS: The median age at transplantation was 21 months (range 12-57 months). Except for one death, all successfully transplanted MPSI-H patients surviving at least 1 year after HSCT are alive to-date, with a median age of 21 years (range 8-36 years) at the last follow-up evaluation. A majority of HSCT grafts were bone marrow transplants (BMT), resulting in durable full chimerism in 18 (72%). Pre-HSCT, the onset of first symptoms occurred very early, at a median age of 3 months (range birth-16 months). The most prevalent symptoms before MPSI-H diagnosis involved progressive dysostosis multiplex; almost all patients suffered from hip dysplasia and thoracolumbar spine Kyphosis. Despite HSCT, considerable residual disease burden and ensuing corrective surgical interventions were observed in all, and at every decade of follow-up post HSCT. Late-onset psychiatric manifestations were significant (n = 17 patients; 68%), including depression in 13 patients at a median onset age of 18 years (range 13-31 years), hyperactivity and attention deficit disorder (n = 4), and multiple acute psychotic episodes (APE), independent of depression observed (n = 3) at a median onset age of 18 years (range 17-31 years). The adult Welscher Intelligence Scale results (n = 16) were heterogenous across the four scale dimensions; overall lower scores were observed on both working memory index (median WMI = 69.5) and processing speed index (median PSI = 65), whereas verbal comprehension index (median VCI = 79) and perceptual reasoning index (median PRI = 74) were higher.
CONCLUSION: With advanced treatment options, MPSI-H are living into 3rd and 4th decades of life, however not disease free and with poor adaptation. Residual disease (loss of mobility, limited gross and fine motor skills; low cognitive ability; suboptimal cardiopulmonary function, vision and hearing) negatively impacts the quality of life and psychosocial functioning of affected individuals.

Entities:  

Keywords:  Adaptation; Cognitive; Depression; Hematopoietic cell transplantation; Long-term outcomes; Mucopolysaccharidosis type I-Hurler syndrome; Psychosocial function; Residual disease burden

Mesh:

Year:  2021        PMID: 33517895      PMCID: PMC7847591          DOI: 10.1186/s13023-020-01644-w

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  56 in total

1.  Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation.

Authors:  Jason S Weisstein; Eliana Delgado; Lynne S Steinbach; Kim Hart; Seymour Packman
Journal:  J Pediatr Orthop       Date:  2004 Jan-Feb       Impact factor: 2.324

2.  Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.

Authors:  Vassili Valayannopoulos; Jacques de Blic; Nizar Mahlaoui; Bertrand Stos; Francis Jaubert; Damien Bonnet; Alain Fischer; Pascale de Lonlay
Journal:  Pediatrics       Date:  2010-10-25       Impact factor: 7.124

3.  A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

Authors:  Monica Sifuentes; Robin Doroshow; Richard Hoft; Greg Mason; Irwin Walot; Michael Diament; Susan Okazaki; Kenneth Huff; Gerald F Cox; Stuart J Swiedler; Emil D Kakkis
Journal:  Mol Genet Metab       Date:  2006-09-29       Impact factor: 4.797

4.  Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres.

Authors:  A Vellodi; E P Young; A Cooper; J E Wraith; B Winchester; C Meaney; U Ramaswami; A Will
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

5.  Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kyle Rudser; Kathleen Delaney; Victor Kovac; Alia Ahmed; Brianna Yund; Paul J Orchard; Julie Eisengart; Gregory R Niklason; Julian Raiman; Eva Mamak; Morton J Cowan; Mara Bailey-Olson; Paul Harmatz; Suma P Shankar; Stephanie Cagle; Nadia Ali; Robert D Steiner; Jeffrey Wozniak; Kelvin O Lim; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2015-06-17       Impact factor: 4.797

6.  An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT).

Authors:  Elsa Shapiro; O Evren Guler; Kyle Rudser; Kathleen Delaney; Kendra Bjoraker; Chester Whitley; Jakub Tolar; Paul Orchard; James Provenzale; Kathleen M Thomas
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

7.  Mucopolysaccharidosis I: management and treatment guidelines.

Authors:  Joseph Muenzer; James E Wraith; Lorne A Clarke
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

8.  The effect of haemopoietic stem cell transplantation on the ocular phenotype in mucopolysaccharidosis type I (Hurler).

Authors:  Ahmed Javed; Tariq Aslam; Simon A Jones; Jean Mercer; Karen Tyler; Heather Church; Arunabha Ghosh; Robert Wynn; Krishanthy Sornalingam; Jane Ashworth
Journal:  Acta Ophthalmol       Date:  2017-12-14       Impact factor: 3.761

Review 9.  Transplant outcomes in mucopolysaccharidoses.

Authors:  Vinod K Prasad; Joanne Kurtzberg
Journal:  Semin Hematol       Date:  2010-01       Impact factor: 3.851

10.  Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children.

Authors:  A Soni-Jaiswal; J Mercer; S A Jones; I A Bruce; P Callery
Journal:  Orphanet J Rare Dis       Date:  2016-07-12       Impact factor: 4.123

View more
  4 in total

1.  Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation.

Authors:  Stefanie Maier; Miroslav Zivicnjak; Lorenz Grigull; Julia B Hennermann; Charlotte Aries; Britta Maecker-Kolhoff; Martin Sauer; Anibh M Das; Rita Beier
Journal:  JIMD Rep       Date:  2022-04-26

2.  Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.

Authors:  Aman Wadhwa; Yanjun Chen; Lindsey Hageman; Elizabeth Schlichting; Erin Funk; Jessica Hicks; Nora Balas; Arianna Siler; Jessica Wu; Liton Francisco; Anna Holmqvist; Ashish Gupta; Troy Lund; Paul J Orchard; Saro Armenian; Mukta Arora; Smita Bhatia
Journal:  Transplant Cell Ther       Date:  2021-12-05

Review 3.  Early Neonatal Cardiac Phenotype in Hurler Syndrome: Case Report and Literature Review.

Authors:  Nishitha R Pillai; Alia Ahmed; Todd Vanyo; Chester B Whitley
Journal:  Genes (Basel)       Date:  2022-07-22       Impact factor: 4.141

Review 4.  Mucopolysaccharidosis: A broad review.

Authors:  Ritu Nagpal; Ram Bharos Goyal; K Priyadarshini; Seema Kashyap; Mohita Sharma; Rajesh Sinha; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.